Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04107766 | NOLA (NeuWave Observational Liver Ablation) Registry | terminated | — | 1,254 | Ethicon, Inc.INDUSTRY | 8 | Apr 17, 2026 | clinicaltrials |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | terminated | Phase 1 / Phase 2 | 2 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04638582 | Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 6 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05488145 | A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy | terminated | N/A | 21 | Emory UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05605119 | First in Human, Dose Escalation, Dose Expansion Study of AUR105(SURYA-1) | terminated | Phase 1 | 17 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics(BHARAT-1) | terminated | Phase 1 | 27 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | terminated | Phase 1 | 21 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05983965 | Study of Tazemetostat in Lymphoid Malignancies | terminated | Phase 1 | 6 | University of Alabama at BirminghamOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06760702 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers(TEJAS-2) | terminated | Phase 2 | 29 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07040059 | A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | terminated | Phase 1 / Phase 2 | 2 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05012124 | Using Technology to Optimize Collaborative Care Management of Depression in Urban and Rural Cancer Centers, SCOPE | terminated | N/A | 297 | University of WashingtonOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05498220 | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 2 | 5 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02095184 | GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients | terminated | N/A | 42 | University of Maryland, BaltimoreOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03856216 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation | terminated | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05397093 | ITIL-306 in Advanced Solid Tumors | terminated | Phase 1 | 1 | Instil BioINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT01507506 | Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma(SPECTRO GLIO) | terminated | Phase 3 | 180 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03846128 | Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer(BIOSUNTOX) | terminated | — | 6 | University Hospital, RouenOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04600466 | Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer | terminated | — | 129 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05189366 | Sophrology Treatment for Patients With Glial Tumours Requiring Speech Therapy(SOPHNEURO) | terminated | N/A | 13 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06088654 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 23 | Innate PharmaINDUSTRY | 3 | Apr 14, 2026 | clinicaltrials |
| NCT00802711 | 3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast Cancer | terminated | N/A | 6 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT01081028 | Connect® MM- The Multiple Myeloma Disease Registry | terminated | — | 3,011 | CelgeneINDUSTRY | 2 | Apr 13, 2026 | clinicaltrials |
| NCT01164150 | Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06 | terminated | Phase 2 | 92 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02151019 | Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer(TRI-LARC) | terminated | Phase 1 / Phase 2 | 94 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02764086 | INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer | terminated | Phase 1 / Phase 2 | 6 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03869762 | Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.(DICE) | terminated | Phase 2 | 7 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04924192 | A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer | terminated | Phase 2 | 21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05518110 | PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer(PaTcH) | terminated | Phase 2 | 20 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05639153 | A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 13 | Zhejiang Doer Biologics Co., Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05879185 | A Study of XmAb23104 in People With Sarcoma | terminated | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02819752 | PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck(PEACH) | terminated | Phase 1 | 3 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04853329 | Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma | terminated | Phase 1 | 7 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05567835 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer(TOGAR) | terminated | Phase 2 | 3 | Baylor College of MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07000344 | A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor | terminated | N/A | 5 | Peking Union Medical College HospitalOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07479381 | Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study(CLEAR) | terminated | — | 14 | Harbinger HealthINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03699995 | MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma | terminated | N/A | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04892017 | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | terminated | Phase 1 | 91 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06034197 | Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy | terminated | Early Phase 1 | 9 | Stephan RogallaOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07035067 | Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada | terminated | — | 24 | PeriPharmOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02679963 | Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer(PIPSeN) | terminated | Phase 2 | 180 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05263271 | Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome | terminated | Phase 1 | 58 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT01366612 | Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation(FLUBUTBI) | terminated | Phase 3 | 53 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02681302 | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence(CPIT001) | terminated | Phase 1 / Phase 2 | 46 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05937672 | Cold Atmospheric Plasma Device Extension Study | terminated | Phase 3 | 60 | Medical University of South CarolinaOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03348748 | Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer | terminated | Early Phase 1 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05618366 | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 | 3 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05744375 | Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab(TRANSCENDER) | terminated | Phase 2 | 2 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05765734 | A Study of TAS3351 in NSCLC Patients With EGFRmt(TAS3351) | terminated | Phase 1 | 18 | Taiho Oncology, Inc.INDUSTRY | 5 | Apr 2, 2026 | clinicaltrials |
| NCT05839119 | Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant(TASUC-Neo) | terminated | Phase 1 | 2 | Brown UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2026source: clinicaltrials